drugset / Trial / NCT03362190
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Timeline
- Start
- 2017-10-11
- Primary completion
- 2018-10-18
- Completion
- 2018-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avacincaptad Pegol | Aptamer | — | Intravitreal |
| Background | Ranibizumab | Monoclonal antibody | 0.5 mg | — |